Conivaptan Hydrochloride Suppliers & Bulk Manufacturers
Available Forms: Infusion
Available Strengths: 20 mg/100 mL
Reference Brands: Vaprisol (USA)
Category:
Critical Care
Conivaptan Hydrochloride is available in Infusion
and strengths such as 20 mg/100 mL.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Conivaptan Hydrochloride is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Conivaptan Hydrochloride can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Conivaptan hydrochloride is a vasopressin receptor antagonist used for the treatment of hyponatremia, a condition characterized by abnormally low sodium levels in the blood. It is commonly prescribed for hospitalized patients with euvolemic or hypervolemic hyponatremia, including cases associated with the syndrome of inappropriate antidiuretic hormone secretion (SIADH), heart failure, or other medical conditions that affect fluid balance. Conivaptan is marketed under the brand name Vaprisol and is administered intravenously in a controlled hospital setting.
Conivaptan works by blocking the action of vasopressin, also known as antidiuretic hormone (ADH), at V1A and V2 receptors. By inhibiting these receptors, the drug promotes the excretion of free water without significant loss of electrolytes, helping to gradually increase serum sodium levels and restore fluid balance in the body. This mechanism makes it particularly useful in managing conditions where excess water retention leads to dilutional hyponatremia.
Approved in 2004, conivaptan has become an important treatment option in critical care and hospital medicine. Its targeted action and controlled administration allow healthcare professionals to effectively manage sodium imbalances while closely monitoring patient response and safety.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing